FDI to upgrade landmark ‘Oral Health Atlas’
In one of its most exciting projects in recent times, FDI is seeking to broaden and update oral health data for a new edition of the landmark ‘Oral Health Atlas’. The Atlas, first issued in 2009, is a unique two-part snapshot of the state of oral health in the world along with the major challenges.
The second part summarizes data for ten indicators, three economic, five oral-health specific and two behavioural. Given the dearth of available information, it represents even today a major achievement for FDI and oral health.
However, the passing years, FDI’s increased focus on oral diseases within the context of United Nations initiatives on noncommunicable diseases, as well as the inevitable inconsistencies of data derived from a variety of sources mean that it is now high time for an upgrade.
The upgrade will take the form of a user-friendly online database—facilitating the process of continuous improvement—incorporating a wide range of robust data derived from indentified and credible sources. Users such as national dental associations, dentists and policy makers will be able to access to raw information and export it in a variety of formats, including tables and maps.
In a second phase, a selection of data will be used to produce a revised version of the Oral Health Atlas and provide relevant information for policy makers and the general public.
The project will be under the leadership of the newly set-up Oral Health Atlas II Task Team. Task Team members are Prof Lijian Jin (Hong Kong), Dr Kevin Hardwick (USA), Valerie Robison (USA), Dr Fannye Thompson (Barbados) and Dr Habib Benzian (Germany).
Funding and support
Development of the Oral Health Atlas, 2nd edition, will be funded by a generous donation from the Hong Kong Dental Association (HKDA).
The online data upgrade is one of the first projects to implement the recommendations and provisions of FDI’s Vision 2020, a project seeking to shape the future of oral health, supported by Colgate, Henry Schein, Ivoclar Vivadent, Johnson & Johnson, Sunstar, and Unilever.